8-K: Tonix Pharmaceuticals Reports Q3 2024 Results, Highlights Progress on Key Drug Candidates

Tonix Pharmaceuticals announced its third quarter 2024 financial results and provided updates on its drug development pipeline, including the submission of a New Drug Application for TNX-102 SL for fibromyalgia.

Summary

• Tonix Pharmaceuticals reported its financial results for the third quarter of 2024, ending September 30, 2024.
• The company submitted a New Drug Application (NDA) to the FDA for TNX-102 SL for fibromyalgia, based on two successful Phase 3 studies.
• The FDA granted Fast Track designation to TNX-102 SL in July 2024, which could expedite the review process.
• Tonix expects an FDA decision on the NDA acceptance in December 2024 and a potential PDUFA date in 2025.
• If approved, TNX-102 SL would be the first new drug for fibromyalgia in over 15 years, targeting a market of approximately 10 million adults in the U.S.
• The company presented new data on its potential mpox vaccine, TNX-801, showing tolerability in immunocompromised animals.
• Tonix was awarded a U.S. Department of Defense contract for up to $34 million over five years to develop a broad-spectrum antiviral drug.
• Net product revenue for the third quarter was approximately $2.8 million, derived from sales of Zembrace SymTouch and Tosymra.
• Research and development expenses decreased to approximately $9.1 million in Q3 2024, compared to $21.0 million in Q3 2023, due to a capital efficient strategy.
• The net loss available to common stockholders was approximately $14.2 million, or $0.23 per share, for the third quarter 2024, compared to a net loss of $28.0 million, or $38.63 per share, for the same period in 2023.
• As of September 30, 2024, Tonix had approximately $28.2 million in cash and cash equivalents.

Sentiment

Score: 7

Explanation: The document presents a mix of positive developments, such as the NDA submission and Fast Track designation, alongside financial losses. The progress in the pipeline and strategic partnerships are encouraging, but the company's financial position and reliance on future funding temper the overall sentiment.

Positives

• The submission of the NDA for TNX-102 SL is a significant milestone for the company.
• The Fast Track designation for TNX-102 SL could expedite the approval process.
• The potential for TNX-102 SL to be the first new fibromyalgia drug in over 15 years represents a substantial market opportunity.
• The positive data on TNX-801's tolerability in immunocompromised animals is encouraging for its development as a mpox vaccine.
• The DoD contract provides significant funding and validation for Tonix's antiviral program.
• The decrease in research and development expenses demonstrates a focus on capital efficiency.
• The company has secured new patents for its migraine products, extending market exclusivity.
• The company has a strong cash position of $28.2 million.

Negatives

• The company reported a net loss of $14.2 million for the third quarter of 2024.
• Net product revenue decreased to $2.8 million in Q3 2024 compared to $3.989 million in Q3 2023.
• The company has a history of significant losses, with a net loss of $107.9 million for the nine months ended September 30, 2024.

Risks

• There is a risk that the FDA may not accept the NDA for TNX-102 SL or may not approve the drug.
• The company faces competition in the pharmaceutical market.
• The company's success depends on the successful development and commercialization of its product candidates.
• The company may need additional financing in the future.
• There are risks associated with patent protection and litigation.
• The company is dependent on third parties for research and development efforts.

Future Outlook

Tonix anticipates an FDA decision on the acceptance of the NDA for TNX-102 SL in December 2024 and a potential PDUFA date in 2025. The company also expects topline results from the Phase 2 CATALYST study of TNX-1300 in the first half of 2025.

Management Comments

• With our recent NDA submission to the U.S. Food and Drug Administration (FDA), Tonix is excited about the potential of TNX-102 SL to become the first new drug treatment option in more than 15 years for the roughly 10 million adults in the U.S. suffering from fibromyalgia, said Seth Lederman, M.D., Chief Executive Officer of Tonix.
• As we continue to advance key pipeline products through a capital efficient strategy, we are excited to have announced collaborations with world-class institutions to advance the development of TNX-801, a potential mpox vaccine whose single-dose administration and other characteristics align closely with The World Health Organizations preferred target product profile (TPP) criteria for mpox vaccines, said Dr. Lederman.

Industry Context

The announcement comes at a time when there is a significant unmet need for new treatments for fibromyalgia, and the mpox outbreak has highlighted the need for effective vaccines. Tonix's focus on these areas positions it to potentially address critical public health challenges.

Comparison to Industry Standards

• The submission of an NDA for TNX-102 SL puts Tonix in a competitive position against other companies developing treatments for fibromyalgia, such as Eli Lilly (Cymbalta) and Pfizer (Lyrica), although these are older drugs.
• The development of TNX-801 as a potential mpox vaccine aligns with global efforts to combat the disease, with companies like Bavarian Nordic also working on mpox vaccines.
• The DoD contract for antiviral development is similar to other government initiatives to support biodefense research, with companies like Emergent BioSolutions also participating in such programs.
• The company's financial results show a decrease in R&D spending, which is a common strategy for smaller biotech companies to manage cash flow, but it is important to compare this to the spending of similar companies such as Biohaven or Neurocrine Biosciences.

Management Changes

Stakeholder Impact

• Shareholders may be positively impacted by the progress of the drug pipeline and potential FDA approvals, but also face risks due to the company's financial losses and need for future funding.
• Employees may benefit from the company's growth and development, but also face uncertainty due to the company's financial situation.
• Patients with fibromyalgia may benefit from the potential approval of TNX-102 SL, which could provide a new treatment option.
• The DoD contract could lead to improved medical readiness for military personnel.
• Customers of Zembrace SymTouch and Tosymra will continue to have access to these migraine treatments.

Next Steps

• The company expects an FDA decision on the acceptance of the NDA for TNX-102 SL in December 2024.
• Tonix anticipates a potential PDUFA date for TNX-102 SL in 2025.
• Topline results from the Phase 2 CATALYST study of TNX-1300 are expected in the first half of 2025.
• Tonix will continue to advance its other pipeline programs, including TNX-801 and TNX-4200.

Key Dates

Keywords

TNX-102 SL, fibromyalgia, mpox vaccine, TNX-801, FDA, NDA, Fast Track Designation, antiviral, DoD contract, Zembrace SymTouch, Tosymra, research and development, financial results, biopharmaceutical